The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells
Open accessAbstract
An important risk in the clinical application of human pluripotent stem cells (hPSCs), including human embryonic and induced pluripotent stem cells (hESCs and hiPSCs), is teratoma formation by residual undifferentiated cells. We raised a monoclonal antibody against hESCs, designated anti–stage-specific embryonic antigen (SSEA)-5, which binds a previously unidentified antigen highly and specifically expressed on hPSCs—the H type-1 glycan. Separation based on SSEA-5 expression through fluorescence-activated cell sorting (FACS) greatly reduced teratoma-formation potential of heterogeneously differentiated cultures. To ensure complete removal of teratoma-forming cells, we identified additional pluripotency surface markers (PSMs) exhibiting a large dynamic expression range during differentiation: CD9, CD30, CD50, CD90 and CD200. Immunohistochemistry studies of human fetal tissues and bioinformatics analysis of a microarray database revealed that concurrent expression of these markers is both common and specific to hPSCs. Immunodepletion with antibodies against SSEA-5 and two additional PSMs completely removed teratoma-formation potential from incompletely differentiated hESC cultures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Embryonic Stem Cell Lines Derived from Human Blastocysts
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., & Jones, J. M. (1998) · Science · doi:10.1126/science.282.5391.1145 · Cited by 15,926
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro
Reubinoff, B. E., Pera, M. F., Fong, C.-Y., Trounson, A., & Bongso, A. (2000) · Nature Biotechnology · doi:10.1038/74447 · Cited by 2,706
Glycosphingolipids in Cellular Interaction, Differentiation, and Oncogenesis
Hakomori, S. (1981) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.50.070181.003505 · Cited by 1,644
Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1).
Solter, D., & Knowles, B. B. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.11.5565 · Cited by 1,294
MULTIPOTENTIALITY OF SINGLE EMBRYONAL CARCINOMA CELLS.
Kleinsmith, L. J., & Pierce, G. B. (1964) · PubMed · Cited by 987
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271
Boiko, A. D., Razorenova, O. V., van de Rijn, M., Swetter, S. M., Johnson, D. L., Ly, D. P., Butler, P. D., Yang, G. P., Joshua, B., Kaplan, M. J., et al. (2010) · Nature · doi:10.1038/nature09161 · Cited by 720
Self-citationKannagi, R., Cochran, N. A., Ishigami, F., Hakomori, S., Andrews, P. W., Knowles, B. B., & Solter, D. (1983) · The EMBO Journal · doi:10.1002/j.1460-2075.1983.tb01746.x · Cited by 545
Hentze, H., Soong, P. L., Wang, S. T., Phillips, B. W., Putti, T. C., & Dunn, N. R. (2009) · Stem Cell Research · doi:10.1016/j.scr.2009.02.002 · Cited by 501
Surface antigens of human embryonic stem cells: changes upon differentiation in culture*
Draper, J. S., Pigott, C., Thomson, J. A., & Andrews, P. W. (2002) · Journal of Anatomy · doi:10.1046/j.1469-7580.2002.00030.x · Cited by 470
Cited by
Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies
Lee, A. S., Tang, C., Rao, M. S., Weissman, I. L., & Wu, J. C. (2013) · Nature Medicine · doi:10.1038/nm.3267 · Cited by 727
Self-citationBurridge, P. W., Keller, G., Gold, J. D., & Wu, J. C. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2011.12.013 · Cited by 670
Self-citationProtein post-translational modifications and regulation of pluripotency in human stem cells
Wang, Y.-C., Peterson, S. E., & Loring, J. F. (2014) · Cell Research · doi:10.1038/cr.2013.151 · Cited by 395
Stem cells in dentistry – Part I: Stem cell sources
Egusa, H., Sonoyama, W., Nishimura, M., Atsuta, I., & Akiyama, K. (2012) · Journal of Prosthodontic Research · doi:10.1016/j.jpor.2012.06.001 · Cited by 374
Ben-David, U., Gan, Q.-F., Golan-Lev, T., Arora, P., Yanuka, O., Oren, Y. S., Leikin-Frenkel, A., Graf, M., Garippa, R., Boehringer, M., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2012.11.015 · Cited by 305
Process engineering of human pluripotent stem cells for clinical application
Serra, M., Brito, C., Correia, C., & Alves, P. M. (2012) · Trends in Biotechnology · doi:10.1016/j.tibtech.2012.03.003 · Cited by 303
Lectin microarrays: concept, principle and applications
Hirabayashi, J., Yamada, M., Kuno, A., & Tateno, H. (2013) · Chemical Society Reviews · doi:10.1039/c3cs35419a · Cited by 303
Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications
Yoshihara, M., Hayashizaki, Y., & Murakawa, Y. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-016-9680-6 · Cited by 283
Inhibition of pluripotent stem cell-derived teratoma formation by small molecules
Lee, M.-O., Moon, S. H., Jeong, H.-C., Yi, J.-Y., Lee, T.-H., Shim, S. H., Rhee, Y.-H., Lee, S.-H., Oh, S.-J., Lee, M.-Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303669110 · Cited by 246
Führmann, T., Tam, R. Y., Ballarin, B., Coles, B., Elliott Donaghue, I., van der Kooy, D., Nagy, A., Tator, C. H., Morshead, C. M., & Shoichet, M. S. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.032 · Cited by 192
Generation of folliculogenic human epithelial stem cells from induced pluripotent stem cells
Yang, R., Zheng, Y., Burrows, M., Liu, S., Wei, Z., Nace, A., Guo, W., Kumar, S., Cotsarelis, G., & Xu, X. (2014) · Nature Communications · doi:10.1038/ncomms4071 · Cited by 125
Gao, X., Wang, X., Xiong, W., & Chen, J. (2016) · Scientific Reports · doi:10.1038/srep22490 · Cited by 73
Strategies to Improve the Safety of iPSC-Derived β Cells for β Cell Replacement in Diabetes
Pellegrini, S., Zamarian, V., & Sordi, V. (2022) · Transplant International · doi:10.3389/ti.2022.10575 · Cited by 38
Choi, S. W., Kim, J.-J., Seo, M.-S., Park, S.-B., Shin, T.-H., Shin, J.-H., Seo, Y., Kim, H.-S., & Kang, K.-S. (2017) · Journal of Veterinary Science · doi:10.4142/jvs.2017.18.1.59 · Cited by 21
The Safety of Embryonic Stem Cell Therapy Relies on Teratoma Removal
Tang, C., Weissman, I. L., & Drukker, M. (2012) · Oncotarget · doi:10.18632/oncotarget.434 · Cited by 12
Self-citationMouse Pluripotent Stem Cell Differentiation Under Physiological Oxygen Reduces Residual Teratomas
Millman, J. R., Tan, J. H., & Colton, C. K. (2021) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-021-00687-8 · Cited by 7
Metadata
- Authors
- Tang, C., Lee, A. S., Volkmer, J.-P., Sahoo, D., Nag, D., Mosley, A. R., Inlay, M. A., Ardehali, R., Chavez, S. L., Pera, R. R., Behr, B., Wu, J. C., Weissman, I. L., & Drukker, M.
- Venue
- Nature Biotechnology
- Published
- 2011-08-14
- Volume
- 29
- Issue
- 9
- Pages
- 829-834
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2047824477
- Cited by
- 375
- References
- 33
- FWCI
- 17.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.